Download and Read Online The Alzheimer S Disease Challenge Book
Download The Alzheimer S Disease Challenge Book PDF, Read Online The Alzheimer S Disease Challenge Book Epub. Ebook The Alzheimer S Disease Challenge Tuebl Download Online. The following is a list of various book titles based on search results using the keyword the alzheimer s disease challenge. Click "GET BOOK" on the book you want. Register now and create a free account to access unlimited books, fast download, ad-free and books in good quality!
Book The Alzheimer's Disease Challenge Description/Summary:
Alzheimer’s disease is undoubtedly the major health challenge of our Century with significant social and economic consequences. This Frontiers eBook offers a contribution of 39 innovative papers on the multidimensional and crucial problem of Alzheimer’s disease management and treatment. Several perspectives, research updates, and trials describing methods on potential diagnosis and treatment are presented including biological mechanisms, biomarkers and risk factors for an early and efficient prognosis, diagnosis and prevention. Additionally, while the rapidly increasing Alzheimer’s disease population demands holistic solutions and clinical studies with new therapeutic target approaches, several of the contributive papers present promising drugs targeting Alzheimer’s disease treatment. We give our deepest acknowledgment to all the authors for their important and innovative contributions, to the reviewers for their valuable recommendations on improving the submitting studies and all the Frontiers Editorial team for continuous support.
There is a wide scope of clinical phenomenology in Alzheimers disease, regarding the age of onset, presenting features, rate of progression and appearance of other clinical manifestation. Although clinical appearance and neuropathological hallmarks have been defining AD since its first description, major factors which trigger pathology are still unknown. The role of comorbidity is discussed controversially. Important environmental risk factors in AD development are continuous stress, low education and cardiovascular risk factors such as alcohol intake, smoking, hypertension. The role of lipids and cholesterol has been recognized, but the relevant pathogenetic steps are still to be identified. There is an urgent need to understand molecular disease pathogenesis in order to develop early therapeutic targets for the disease.
Book Developing Therapeutics for Alzheimer's Disease Description/Summary:
Developing Therapeutics for Alzheimer's Disease: Progress and Challenges provides a thorough overview of the latest advances toward the development of therapeutics for Alzheimer’s disease, along with the major hurdles that still must be overcome and potential solutions to these problems. Despite the lack of progress toward developing therapeutics that can slow or stop the progression of this disease, important discoveries have been made and many promising approaches are advancing in preclinical studies and clinical trials. This book outlines the special challenges related to specific targets and approaches, while presenting a realistic, comprehensive and balanced view of drug discovery and development in this area. Written by international leaders in the field, the book assesses prospects for the emergence of effective agents and allows readers to better understand the challenges, failures, and future potential for research in Alzheimer’s disease. This book is a valuable resource to academic scientists carrying out translational research in Alzheimer’s disease, industrial scientists engaged in Alzheimer's drug discovery, executives in biopharmaceutical companies making strategic decisions regarding the direction of internal research and potential outside partnerships, and graduate-level students pursuing courses on Alzheimer's therapeutics. Provides a realistic but promising assessment of the potential of various therapeutic approaches to Alzheimer’s disease Focuses primarily on neuroprotective agents and cognitive enhancers, as well as approaches to targeting the amyloid B-peptide, tau and Apolipoprotein E Discusses alternative approaches, preclinical and clinical development issues, related biomarkers and diagnostics, and prevention and nonpharmacological approaches
Alzheimer's disease was discovered over 100 years ago and still belongs to incurable neurological diseases; its pharmacotherapy is considered to be ineffective. This book presents contemporary views on the genetic, biochemical, and immunological determinants of this disease. This book also concerns the issue of Alzheimer's disease prevention through lifestyle and physical activity. Moreover, it describes the therapies used in Alzheimer's disease to slow the progression of the disease and delay its onset. Subsequently, the authors discuss experimental and clinical trials used now and in the near future. We hope that this book will help the readers to understand the complex mechanism leading to the development of Alzheimer's disease and indicate effective ways to prevent this disorder.
Book The Moral Challenge of Alzheimer Disease Description/Summary:
Society today, writes Stephen Post, is "hypercognitive": it places inordinate emphasis on people's powers of rational thinking and memory. Thus, Alzheimer disease and other dementias, which over an extended period incrementally rob patients of exactly those functions, raise many dilemmas. How are we to view—and value—persons deprived of what some consider the most important human capacities? In the second edition of The Moral Challenge of Alzheimer Disease, Post updates his highly praised account of the major ethical issues relating to dementia care. With chapters organized to follow the progression from mild to severe and then terminal stages of dementia, Post discusses topics including the experience of dementia, family caregiving, genetic testing for Alzheimer disease, quality of life, and assisted suicide and euthanasia. New to this edition are sections dealing with end-of-life issues (especially artificial nutrition and hydration), the emerging cognitive-enhancing drugs, distributive justice, spirituality, and hospice, as well as a critique of rationalistic definitions of personhood. The last chapter is a new summary of practical solutions useful to family members and professionals. -- Peter M. Jucovey
Book Drug Design and Discovery in Alzheimer’s Disease Description/Summary:
Drug Design and Discovery in Alzheimer’s Disease includes expert reviews of recent developments in Alzheimer's disease (AD) and neurodegenerative disease research. Originally published by Bentham as Frontiers in Drug Design and Discovery, Volume 6and now distributed by Elsevier, this compilation of the sixteen articles, written by leading global researchers, focuses on key developments in the understanding of the disease at molecular levels, identification and validation of molecular targets, as well as innovative approaches towards drug discovery, development, and delivery. Beginning with an overview of AD pharmacotherapy and existing blockbuster drugs, the reviews cover the potential of both natural and synthetic small molecules; the role of cholinesterases in the on-set and progression of AD and their inhibition; the role of beta-site APP clearing enzyme-1 (BACE-1) in the production of ß-amyloid proteins, one of the key reasons of the progression of AD; and other targets identified for AD drug discovery. Edited and written by leading experts in Alzheimer’s disease (AD) and other neurodegenerative disease drug development Describes existing drugs for AD and current molecular understanding of the condition Reviews recent advances in the field, including coverage of cholinesterases, BACE-1, and other drug development targets
Book The Problem of Alzheimer's Description/Summary:
A definitive and compelling book on one of today's most prevalent illnesses. In 2020, an estimated 5.8 million Americans had Alzheimer’s, and more than half a million died because of the disease and its devastating complications. 16 million caregivers are responsible for paying as much as half of the $226 billion annual costs of their care. As more people live beyond their seventies and eighties, the number of patients will rise to an estimated 13.8 million by 2025. Part case studies, part meditation on the past, present and future of the disease, The Problem of Alzheimer's traces Alzheimer’s from its beginnings to its recognition as a crisis. While it is an unambiguous account of decades of missed opportunities and our health care systems’ failures to take action, it tells the story of the biomedical breakthroughs that may allow Alzheimer’s to finally be prevented and treated by medicine and also presents an argument for how we can live with dementia: the ways patients can reclaim their autonomy and redefine their sense of self, how families can support their loved ones, and the innovative reforms we can make as a society that would give caregivers and patients better quality of life. Rich in science, history, and characters, The Problem of Alzheimer's takes us inside laboratories, patients' homes, caregivers’ support groups, progressive care communities, and Jason Karlawish's own practice at the Penn Memory Center.
USGPO Staff,United States,United States. Congress. Senate. Committee on Labor and Human Resources. Subcommittee on Aging
Author : USGPO Staff,United States,United States. Congress. Senate. Committee on Labor and Human Resources. Subcommittee on Aging
Publisher : Unknown
Release : 1997
Category : Alzheimer's disease
ISBN : PSU:000031688536
Book Alzheimer’s Disease Theranostics Description/Summary:
Alzheimer’s Disease Theranostics discusses the latest information on recent theranostic avenues for both the diagnosis and treatment of Alzheimer’s patients. It presents the pros and cons of the probable mechanistic role of nanoparticles in crossing the blood-brain barrier and improving disease symptoms. Finally, it highlights the merits of existing maneuvers and suggests perspectives to aid in future developments. Despite the difficulty of drug delivery to the brain, there are some nanoparticulate platforms demonstrating promise in treating neurodegenerative disorders such as Alzheimer’s disease. Manifold theranostic maneuvers include antioxidants, natural bioactive compounds, gene therapy, and nanotechnological approaches, all of which are discussed in this important work. Examines various theranostic applications for the diagnosis and treatment of Alzheimer’s disease Features a comprehensive overview of nanoparticle therapeutics in the area and use of antioxidants Assesses the common challenges and lessons learned from blood-brain barrier challenges, viral vector approaches and mitochondria-targeted therapeutics
Book Predictive Intelligence in Medicine Description/Summary:
This book constitutes the proceedings of the Second International Workshop on Predictive Intelligence in Medicine, PRIME 2019, held in conjunction with MICCAI 2019, in Shenzhen, China, in October 2019. The 18 papers presented in this volume were carefully reviewed and selected for inclusion in this book. The contributions describe new cutting-edge predictive models and methods that solve challenging problems in the medical field for a high-precision predictive medicine.
Book The Person with Alzheimer's Disease Description/Summary:
Few families are untouched by Alzheimer's disease or a related dementia. Moving accounts of what it is like to care for someone with this disease have already been published, as well as how-to books that offer caregivers advice and information on coping. But this book is the first to provide a comprehensive report of what it is like to have dementia oneself—the subjective experience of living with progressive memory loss. Each chapter discusses a different aspect of having dementia, from the initial assessment and diagnosis through placement in a nursing home. The discussions are grounded in qualitative research and case studies, which convey the variable and personal nature of the experience. They seek to help clinicians, researchers, students, and caregivers (both professionals and family members) understand the experience of dementia, and thereby to promote better caregiving through a person-centered approach. Contributors: Kathleen Kahn-Denis, Judson Retirement Community; Casey Durkin, a psychotherapist in Cleveland, Ohio; Jane Gilliard, Dementia Voice, UK; Phyllis Braudy Harris, John Carroll University; John Keady, University of Wales, UK; John Killick, University of Stirling, UK; Rebecca G. Logsdon, University of Washington; Charlie Murphy, University of Stirling, UK; Alison Phinney, University of British Columbia, Canada; Steven R. Sabat, Georgetown University; Dorothy Seman, Alzheimer's Family Care Center, Chicago; Lisa Snyder, University of California, San Diego; Jane Stansell, Alzheimer's Family Care Center, Chicago; Gloria Sterin, Shaker Heights, Ohio; Jon C. Stuckey, Messiah College; Robyn Yale, Consultant to the Alzheimer's Association, San Francisco; Rosalie Young, Wayne State University School of Medicine.
Neurofibrillary tangles (NFTs) composed of intracellular aggregates of tau protein are a key neuropathological feature of Alzheimer’s Disease (AD) and other neurodegenerative diseases, collectively termed tauopathies. The abundance of NFTs has been reported to correlate positively with the severity of cognitive impairment in AD. However, accumulating evidences derived from studies of experimental models have identified that NFTs themselves may not be neurotoxic. Now, many of tau researchers are seeking a “toxic” form of tau protein. Moreover, it was suggested that a “toxic” tau was capable to seed aggregation of native tau protein and to propagate in a prion-like manner. However, the exact neurotoxic tau species remain unclear. Because mature tangles seem to be non-toxic component, “tau oligomers” as the candidate of “toxic” tau have been investigated for more than one decade. In this topic, we will discuss our consensus of “tau oligomers” because the term of “tau oligomers” [e.g. dimer (disulfide bond-dependent or independent), multimer (more than dimer), granular (definition by EM or AFM) and maybe small filamentous aggregates] has been used by each researchers definition. From a biochemical point of view, tau protein has several unique characteristics such as natively unfolded conformation, thermo-stability, acid-stability, and capability of post-translational modifications. Although tau protein research has been continued for a long time, we are still missing the mechanisms of NFT formation. It is unclear how the conversion is occurred from natively unfolded protein to abnormally mis-folded protein. It remains unknown how tau protein can be formed filaments [e.g. paired helical filament (PHF), straight filament and twisted filament] in cells albeit in vitro studies confirmed tau self-assembly by several inducing factors. Researchers are still debating whether tau oligomerization is primary event rather than tau phosphorylation in the tau pathogenesis. Inhibition of either tau phosphorylation or aggregation has been investigated for the prevention of tauopathies, however, it will make an irrelevant result if we don’t know an exact target of neurotoxicity. It is a time to have a consensus of definition, terminology and methodology for the identification of “tau oligomers”.
Book Ethical Foundations of Palliative Care for Alzheimer Disease Description/Summary:
Alzheimer disease afflicts more than twelve million people worldwide, and its incidence is increasing at a staggering rate. People with the disorder are living longer than have those in previous generations, and they require interventions for quality-of-life issues associated with palliative care. However, the symptoms of Alzheimer disease often fail to place such persons into settings where palliative care resources are available to them. Indeed, clinicians and other caregivers may be unsure about what constitutes effective palliation in these cases. At the same time, the ethical issues involved in providing end-of-life care to persons with Alzheimer disease remain on the margins of mainstream bioethics. In Ethical Foundations of Palliative Care for Alzheimer Disease, leading ethicists and clinicians from the United States and Europe explore ethical and scientific concerns about the diagnosis and prognosis of Alzheimer disease, challenges arising from applying palliative procedures to its symptoms, key philosophical and theological concepts central to our understanding of the disease and to end-of-life decisions, and the changing patterns of relevant medical, social, and economic policies. Cross-cultural, multidisciplinary, and state-of-the-art, this volume is a unique and important resource for bioethicists, clinicians, and policy makers everywhere. Contributors: David A. Bennahum, M.D., University of New Mexico; Pierre Boitte, Ph.D., Catholic University of Lille, France; Roger A. Brumback, M.D., Creighton University Medical Center; Wim J. M. Dekkers, M.D., Ph.D., University Medical Centre Nijmegen, The Netherlands; Elizabeth Furlong, R.N., Ph.D., J.D., Creighton University Medical Center; Eugenijus Gefenas, M.D., Ph.D., Vilnius University, Lithuania; Bert Gordijn, Ph.D., University Medical Centre Nijmegen, The Netherlands; Amy M. Haddad, R.N., Ph.D., Creighton University Medical Center; SÃ¸ren Holm, M.D., Ph.D., Dr.Med.Sci., University of Manchester; Franz J. Illhardt, D.D., Ph.D., Freiburg University; Rien Janssens, Ph.D., University Medical Centre Nijmegen, The Netherlands; Givi Javashvili, M.D., Ph.D., State Medical Academy of Georgia, Tbilisi; Judith Lee Kissell, Ph.D., Creighton University Medical Center; Gunilla Nordenram, D.D.S., Ph.D., Karolinska Institute, Stockholm; Richard L. O'Brien, M.D., Creighton University Medical Center; Marcel G. M. Olde Rikkert, M.D., Ph.D., University Medical Centre Nijmegen, The Netherlands; Winifred J. Ellenchild Pinch, R.N., Ed.D., Creighton University Medical Center; Patricio F. Reyes, M.D., Creighton University Medical Center; Anne-Sophie Rigaud, M.D., Ph.D., HÃ´pital Broca, Paris; Linda S. Scheirton, Ph.D., Creighton University Medical Center; Jos V. M. Welie, M.Med.S., J.D., Ph.D., Creighton University Medical Center.
In recent years, a tremendous amount of effort has been focused on better understanding the fundamentals of Alzheimer’s disease (AD) to facilitate early and accurate diagnosis and appropriately targeted therapeutic treatments. Alzheimer’s Disease: Targets for New Clinical, Diagnostic, and Therapeutic Strategies provides a detailed synopsis of the current state of the art of diagnostics and therapeutics and identifies emerging technologies and molecules that show promise in the management and treatment of AD. With contributions from experts drawn from academia, clinical practice, and the biotechnology and pharmaceutical industries, the book explores: The basis of AD and the role of Aβ oligomers in development of disease Existing and emerging in vitro biomarker-based methodologies for the diagnosis of AD, focusing on genetic, biochemical, and conformational strategies In vivo imaging diagnostic approaches Evolving diagnostic criteria, health regulatory guidelines, biomarkers in clinical trials, and available and emerging therapies Recent progress in small-molecule disease-modifier drug discovery efforts for AD, specifically in the areas of Aβ, tau, and emerging neuroprotective/neurorepair approaches How a case study of AD raises issues regarding clinical and pathologic criteria, risk factors, and the amyloid hypothesis The molecular conformational factors that govern the pathogenicity of aggregating proteins, and how these factors could represent new targets for disease-modifying therapies The latest epidemiological, pathological, biochemical, and behavioral studies that may shed some light on the risk of developing AD and similar dementias after traumatic brain injury Examining current hypotheses and suggesting possible new approaches to therapeutic clinical applications, this volume paves the way for a robust pipeline of therapeutics to combat not only AD, but a whole host of other neurodegenerative diseases.
Book Coping with Communication Challenges in Alzheimer's Disease Description/Summary:
This book was written by caregivers of people suffering from Alzheimer's disease and similar progressive dementias. One of the cognitive functions affected by progressive dementia is communication. The author's intent in writing this book was to help caregivers understand the importance of communication, how it changes with the progression of Alzheimer's disease, and what can be done to facilitate good communication between them and their member suffering from the diseasae. Strategies are provided that take into consideration the communicative abilities and difficulties at the three stages of the disease. It also addresses communication between family members and health care professions and among concerned family members and friends. Readers are provided with an extensive list of resources: helpful organizations and agencies, hotlines, and books. The insightful and thoughtful recommendations will help caregivers cope with the changes in their loved one more effectively and successfully.
Alzheimer's disease is becoming more common in Europe, with significant human, ethical, economic and professional challenges to society. This book examines clinical practice and service delivery, and identifies policy issues that could lead to improved quality of life for sufferers and carers. The book: • Describes the differing needs of sufferers and carers, and how they can be met by a co-ordinated approach to policy and implementation • Outlines the particular challenges that healthcare policy makers face for this disease • Shows how better models of service provision can be developed and describes best practice models • Discusses the lessons to be learnt from various European pioneering projects This is a concise and practical guide for clinical specialists including psychiatrists, geriatricians, neurologists, public health doctors, nurses, and policy makers and shapers in health and social services.
United States. Congress. House. Committee on Foreign Affairs. Subcommittee on Africa, Global Health, Global Human Rights, and International Organizations
Author : United States. Congress. House. Committee on Foreign Affairs. Subcommittee on Africa, Global Health, Global Human Rights, and International Organizations
Publisher : Unknown
Release : 2014
Category : Alzheimer's disease
ISBN : MINN:31951D03653128Q
Book The Alzheimer's Prevention Program Description/Summary:
Want to keep Alzheimer’s at bay for years—ideally, forever? Prevention is the way, and this is the guide. Now in paperback and updated throughout, The Alzheimer’s Prevention Program is essential for everyone with a family history of Alzheimer’s, and for the 80 million baby boomers who worry whenever they forget someone’s name. It’s the book that shows how to strengthen memory and avoid everyday lapses. How to incorporate the top ten brain-protecting foods into your diet. How to cross-train your brain, exercising both the right and left hemisphere. And how to reduce stress, a risk factor for developing dementia and Alzheimer’s, through meditation and 11 other relaxation strategies. Written by the New York Times bestselling authors of The Memory Bible, this book is an easy-to-follow regimen based on the latest comprehensive research into Alzheimer’s disease, and especially the critical connection between lifestyle and susceptibility. The paperback edition is updated with a brand-new section that answers the most compelling questions asked of Dr. Small after publication of the first edition, including: the power of exercise to offset a genetic predisposition; antibodies that can clear Alzheimer’s plaques from the brain; and promising new treatments, from drugs to deep brain stimulation. It’s the science-based, breakthrough program that will bring mental clarity to every day and help you take control of your brain’s health.